Fluidigm Jumps on Guidance Boost - Analyst Blog

By
A A A

Shares of Fluidigm Corporation ( FLDM ) rallied 7.2% as it released a solid fiscal 2014 revenue guidance along with its preliminary unaudited results for the fourth quarter of 2013 yesterday. This provider of microfluidic systems in growth markets is slated to release its exhaustive fourth-quarter and fiscal 2013 results in February.

A Look at Elementary Results and Guidance

The company expects to report balanced quarterly sales across both of its instruments and consumable segments. Instrument revenue is expected to peg at $12 million while consumables revenue is projected at $8.5 million, both showing solid 25.0% and 47.8% year-over-year growth respectively. The current Zacks Consensus Estimate for Fluidigm's total revenue remains at $19 million.


Fluidigm is expected to exit the fourth quarter with instrument installed base of 920 units, considerably higher than the year ago figure of 670 units. The company also foresees strong momentum in the single-cell genomics market that covers almost half of the company's product revenue.

Management expects Single-cell genomics revenue to gain twofold in 2013. For the full year 2013, the company expects to report revenues of $71 million, an annualized growth of 35.7% as well as a beat to the Zacks Consensus estimate of $70 million.

We note that, expecting a strong fourth quarter, Fludigm provided a strong outlook for full year 2014. The company anticipates a huge 23%−28% annualized revenue growth in the upcoming fiscal. The Zacks Consensus Estimate of $85 million, representing a growth of 19.7% remains below the projected range.

Fluidigm currently carries a Zacks Rank #3 (Hold). While we choose to remain on the sidelines regarding FLDM at present, better-ranked medical stocks worth considering include Natus Medical Inc. ( BABY ), CryoLife Inc. ( CRY ) and Cepheid ( CPHD ). While Natus Medical and CryoLife sport a Zacks Rank #1 (Strong Buy), Cepheid holds a Zacks Rank #2 (Buy).



NATUS MEDICAL (BABY): Free Stock Analysis Report

CEPHEID INC (CPHD): Free Stock Analysis Report

CRYOLIFE INC (CRY): Free Stock Analysis Report

FLUIDIGM CORP (FLDM): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BABY , CPHD , CRY , FLDM

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

27,471,276
  • $17.6801 ▲ 0.86%
23,135,233
  • $112.925 ▲ 0.24%
22,977,804
  • $47.84 ▲ 0.67%
20,439,672
  • $25.2335 ▲ 0.37%
17,051,543
  • $27.73 ▲ 0.29%
16,864,275
  • $36.81 ▼ 0.57%
14,561,824
  • $9.57 ▼ 4.97%
12,551,513
  • $79.6135 ▲ 1.55%
As of 12/19/2014, 10:13 AM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com